InvestorsHub Logo
Followers 5
Posts 566
Boards Moderated 0
Alias Born 04/25/2013

Re: fishhunter post# 2056

Monday, 04/15/2019 5:12:55 PM

Monday, April 15, 2019 5:12:55 PM

Post# of 2104
In 2016, few months after Tobira failed to meet the primary endpoint for its NASH trial, was purchased for 1.7 billion by Allergan. Just because they miss the primary endpoint doesn’t mean that it is a complete failure. They look for other parameters.